View full meeting coverage »

Eyetube Meeting Coverage:

EURETINA 2020

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

RGX-314 for Wet AMD

  Channels: Retina | Posted 10/5/2020

Robert L. Avery, MD, shares data from a phase 1/2a study that evaluated the safety and efficacy of RGX-314 (RegenxBio) for the treatment of wet AMD. Dr. Avery provides an update on the most recent readouts of the trial and previews forthcoming trials in wet AMD and diabetic retinopathy.

Clinical Trials • Diabetic Retinopathy • gene therapy • REGENXBIO • retina-meeting-recap • Wet AMD


6 / 6 Series: EURETINA 2020